Endothelin-a receptor antagonists prevent amyloid-β-induced increase in ETA receptor expression, oxidative stress, and cognitive impairment

Journal of Alzheimer's Disease

Volumn 23, Issue 3, 2011, Pages 491-503

  Briyal, Seema ^a   Philip, Tina ^a   Gulati, Anil ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; amyloid ; BQ123; cognitive deficit; endothelin; Morris water maze; oxidative stress; rats

Indexed keywords

5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; AMYLOID BETA PROTEIN[1-40]; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GLUTATHIONE; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TAK 044;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN STEM; BRAIN VENTRICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HIPPOCAMPUS; LEARNING; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; SPATIAL MEMORY;

EID: 79951861981     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101245     Document Type: Article

References (85)

1. Johnson DK, Storandt M, Morris JC, Langford ZD, Galvin JE (2008) Cognitive profiles in dementia: Alzheimer disease vs healthy brain aging. Neurology 71, 1783-1789.
2. Dietrich HH, Xiang C, Han BH, Zipfel GJ, Holtzman DM (2010) Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol Neurodegener 5, 15.
3. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
4. Gouras GK, Tsai J, Naslund J,Vincent B, Edgar M, Checler F, Greenfield JP, HaroutunianV, Buxbaum JD, Xu H, Greengard P, Relkin NR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156, 15-20. (Pubitemid 30644433)
5. Wirths O, Multhaup G, Bayer TA (2004) A modified betaamyloid hypothesis: intraneuronal accumulation of the betaamyloid peptide - the first step of a fatal cascade. J Neurochem 91, 513-520. (Pubitemid 39431147)
6. Christie R,Yamada M, Moskowitz M, HymanB(2001) Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol 158, 1065-1071. (Pubitemid 32221798)
7. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ (2008) Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci 28, 13542-13550.
8. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C (2002) Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 283, H315-H323. (Pubitemid 34705353)
9. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, Carlson GA, Iadecola C (2000) Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A 97, 9735-9740. (Pubitemid 30650845)
10. Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, Mullan M (2004) Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res 999, 53-61. (Pubitemid 38121450)
11. Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, Frosch MP, Hyman BT, Moskowitz MA, Ayata C (2007) Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain 130, 2310-2319. (Pubitemid 47327629)
12. ZhangWW, Badonic T, Hoog A, Jiang MH, Ma KC, Nie XJ, Olsson Y (1994) Astrocytes in Alzheimer's disease express immunoreactivity to the vaso-constrictor endothelin-1. J Neurol Sci 122, 90-96. (Pubitemid 24073756)
13. Niwa K, Carlson GA, Iadecola C (2000) Exogenous Abeta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 20, 1659-1668.
14. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C (2001) A beta-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 281, H2417-H2424.
15. Price JM, Sutton ET, Hellermann A, Thomas T (1997) Betaamyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res 19, 534-538. (Pubitemid 27419426)
16. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, Iadecola C (2005) NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci 25, 1769-1777. (Pubitemid 40279282)
17. Paris D, Parker TA, Town T, Suo Z, Fang C, Humphrey J, Crawford F, Mullan M (1998) Role of peroxynitrite in the vasoactive and cytotoxic effects of Alzheimer's betaamyloid1- 40 peptide. Exp Neurol 152, 116-122. (Pubitemid 28366972)
18. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639. (Pubitemid 39061671)
19. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795. (Pubitemid 44622683)
20. Sayre LM, Perry G, Smith MA (2008) Oxidative stress and neurotoxicity. Chem Res Toxicol 21, 172-188. (Pubitemid 351219718)
21. Nitta A, Fukuta T, Hasegawa T, Nabeshima T (1997) Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn J Pharmacol 73, 51-57. (Pubitemid 27078010)
22. Wang R, Zhang HY, Tang XC (2001) Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur J Pharmacol 421, 149-156. (Pubitemid 32539415)
23. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT (2004) Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci 1012, 153-163. (Pubitemid 38453522)
24. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168-171.
25. Crawford F, Suo Z, Fang C, Mullan M (1998) Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp Neurol 150, 159-168. (Pubitemid 28146435)
26. Gulati A, Kumar A, Morrison S, Shahani BT (1997) Effect of centrally administered endothelin agonists on systemic and regional blood circulation in the rat: role of sympathetic nervous system. Neuropeptides 31, 301-309. (Pubitemid 27394774)
27. Gulati A,Kumar A, ShahaniBT(1996) Cardiovascular effects of centrally administered endothelin-1 and its relationship to changes in cerebral blood flow. Life Sci 58, 437-445. (Pubitemid 26188084)
28. Gulati A, Rebello S, Kumar A (1997) Role of sympathetic nervous system in cardiovascular effects of centrally administered endothelin-1 in rats. Am J Physiol 273, H1177-H1186.
29. Gulati A, Rebello S, Roy S, Saxena PR (1995) Cardiovascular effects of centrally administered endothelin-1 in rats. J Cardiovasc Pharmacol 26, S244-S246.
30. Lee ME, de la Monte SM, Ng SC, Bloch KD, Quertermous T (1990) Expression of the potent vasoconstrictor endothelin in the human central nervous system. J Clin Invest 86, 141-147. (Pubitemid 20226986)
31. Thomas T, McLendon C, Sutton ET, Thomas G (1997) Cerebrovascular endothelial dysfunction mediated by betaamyloid. Neuroreport 8, 1387-1391. (Pubitemid 27242542)
32. Zhang WW, Badonic T, Hoog A, Jiang MH, Ma KC, Nie JX, Olsson Y, Sourander P (1994) Structural and vasoactive factors influencing intracerebral arterioles in cases of vascular dementia and other cerebrovascular disease: a review. Immunohistochemical studies on expression of collagens, basal lamina components and endothelin-1. Dementia 5, 153-162. (Pubitemid 24151538)
33. Gupta YK, Briyal S, Sharma U, Jagannathan NR, Gulati A (2005) Effect of endothelin antagonist (TAK-044) on cerebral ischemic volume, oxidative stress markers and neurobehavioral parameters in the middle cerebral artery occlusion model of stroke in rats. Life Sci 77, 15-27. (Pubitemid 40546373)
34. Ozdemir R, Parlakpinar H, Polat A, Colak C, Ermis N, Acet A (2006) Selective endothelin a (ETA) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology 219, 142-149. (Pubitemid 43120714)
35. Kiris I, Narin C, Gulmen S,Yilmaz N, Sutcu R, KapucuogluN (2009) Endothelin receptor antagonism by tezosentan attenuates lung injury induced by aortic ischemia-reperfusion. Ann Vasc Surg 23, 382-391.
36. Callera GE, Touyz RM, Teixeira SA, Muscara MN, Carvalho MH, Fortes ZB, Nigro D, Schiffrin EL, Tostes RC (2003) ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 42, 811-817. (Pubitemid 37237330)
37. Elgebaly MM, Portik-DobosV, Sachidanandam K, Rychly D, Malcom D, Johnson MH, Ergul A (2007) Differential effects of ET(A) and ET(B) receptor antagonism on oxidative stress in type 2 diabetes. Vascul Pharmacol 47, 125-130. (Pubitemid 47095454)
38. Gulati A, Sharma AC, Robbie G, Saxena PR (1995) Endothelin ETA receptor antagonist, BQ-123, blocks the vasoconstriction induced by sarafotoxin 6b in the heart but not in other vascular beds. Gen Pharmacol 26, 183-193.
39. Bhalla S, Matwyshyn G, Gulati A (2003) Endothelin receptor antagonists restore morphine analgesia in morphine tolerant rats. Peptides 24, 553-561. (Pubitemid 36829344)
40. Lavhale MS, Briyal S, Parikh N, Gulati A (2010) Endothelin modulates the cardiovascular effects of clonidine in the rat. Pharmacol Res 62, 489-499.
41. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193, 265-275.
42. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95, 351-358. (Pubitemid 9194347)
43. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82, 70-77.
44. Kakkar P, Das B, Viswanathan PN (1984) A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys 21, 130-132. (Pubitemid 15207169)
45. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11, 47-60. (Pubitemid 14088970)
46. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy- Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2, 864-870. (Pubitemid 26296755)
47. Jarrett JT, Berger EP, Lansbury PT Jr (1993) The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci 695, 144-148. (Pubitemid 23348252)
48. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE (1998) Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 153, 725-733. (Pubitemid 28419027)
49. Suo Z, Humphrey J, Kundtz A, Sethi F, Placzek A, Crawford F, Mullan M (1998) Soluble Alzheimers beta-amyloid constricts the cerebral vasculature in vivo. Neurosci Lett 257, 77-80. (Pubitemid 28552892)
50. Smith CC, Stanyer L, Betteridge DJ (2004) Soluble betaamyloid (Abeta) 40 causes attenuation or potentiation of noradrenaline-induced vasoconstriction in rats depending upon the concentration employed. Neurosci Lett 367, 129-132. (Pubitemid 39078800)
51. Ahmed T, Enam SA, Gilani AH (2010) Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease. Neuroscience 169, 1296-1306.
52. Cullen WK, Suh YH, Anwyl R, Rowan MJ (1997) Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8, 3213-3217. (Pubitemid 27461369)
53. Lopes JP, Oliveira CR, Agostinho P (2010) Neurodegeneration in an Abeta-induced model of Alzheimer's disease: the role of Cdk5. Aging Cell 9, 64-77.
54. Nitta A, Itoh A, Hasegawa T, Nabeshima T (1994) beta- Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 170, 63-66.
55. Pamplona FA, Pandolfo P, Duarte FS, Takahashi RN, Prediger RD (2010) Altered emotionality leads to increased pain tolerance in amyloid beta (Abeta1-40) peptide-treated mice. Behav Brain Res 212, 96-102.
56. Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M (2009) Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 54, 782-787.
57. Frautschy SA, Yang F, Calderon L, Cole GM (1996) Rodent models of Alzheimer's disease: ratAbeta infusion approaches to amyloid deposits. Neurobiol Aging 17, 311-321. (Pubitemid 26167642)
58. Tang F, Nag S, Shiu SY, Pang SF (2002) The effects of melatonin and Ginkgo biloba extract on memory loss and choline acetyltransferase activities in the brain of rats infused intracerebroventricularly with beta-amyloid 1-40. Life Sci 71, 2625-2631. (Pubitemid 35279305)
59. Hardy J, Gwinn-Hardy K (1998) Genetic classification of primary neurodegenerative disease. Science 282, 1075-1079. (Pubitemid 28516229)
60. Greene JD, Baddeley AD, Hodges JR (1996) Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia 34, 537-551. (Pubitemid 26154491)
61. Pillon B, Deweer B, Agid Y, Dubois B (1993) Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol 50, 374-379. (Pubitemid 23105460)
62. Du J, Sun B, Chen K, Zhang L, Liu S, Gu Q, Fan L, Zhao N, Wang Z (2009) Metabolites of cerebellar neurons and hippocampal neurons play opposite roles in pathogenesis of Alzheimer's disease. PLoS One 4, e5530.
63. Gulati A, Rebello S (1992) Characteristics of endothelin receptors in the central nervous system of spontaneously hypertensive rats. Neuropharmacology 31, 243-250.
64. Kumar A, Morrison S, GulatiA(1997) Effect of ETAreceptor antagonists on cardiovascular responses induced by centrally administered sarafotoxin 6b: role of sympathetic nervous system. Peptides 18, 855-864. (Pubitemid 27400215)
65. Kumar A, Shahani BT, Gulati A (1996) Modification of systemic and regional circulatory effects of intracerebroventricular administration of endothelin-1 by propranolol in anesthetized rats. Gen Pharmacol 27, 1025-1033. (Pubitemid 26345058)
66. Rebello S, Roy S, Saxena PR, Gulati A (1995) Systemic hemodynamic and regional circulatory effects of centrally administered endothelin-1 are mediated through ETA receptors. Brain Res 676, 141-150.
67. Yoshizawa T, Iwamoto H, Mizusawa H, Suzuki N, Matsumoto H, Kanazawa I (1992) Cerebrospinal fluid endothelin-1 in Alzheimer's disease and senile dementia of Alzheimer type. Neuropeptides 22, 85-88.
68. Minami M, Kimura M, Iwamoto N, AraiH(1995) Endothelin- 1-like immunoreactivity in cerebral cortex of Alzheimer-type dementia. Prog Neuropsychopharmacol Biol Psychiatry 19, 509-513.
69. Kohzuki M, Onodera H, Yasujima M, Itoyama Y, Kanazawa M, Sato T, Abe K (1995) Endothelin receptors in ischemic rat brain and Alzheimer brain. J Cardiovasc Pharmacol 26(Suppl 3), S329-S331.
70. Yagami T, Ueda K, Asakura K, Kuroda T, Hata S, Sakaeda T, Kambayashi Y, Fujimoto M (2002) Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. Brain Res 948, 72-81. (Pubitemid 35283763)
71. Price JM, Chi X, Hellermann G, Sutton ET (2001) Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol Res 23, 506-512. (Pubitemid 32642784)
72. Elesber AA, Bonetti PO,Woodrum JE, Zhu XY, Lerman LO, Younkin SG, Lerman A (2006) Bosentan preserves endothelial function in mice overexpressing APP. Neurobiol Aging 27, 446-450. (Pubitemid 43185330)
73. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA (1994) A model for betaamyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci U S A 91, 3270-3274.
74. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 68, 255-264. (Pubitemid 26427315)
75. Murakami K, Irie K, Ohigashi H, Hara H, Nagao M, Shimizu T, Shirasawa T (2005) Formation and stabilization model of the 42-mer Abeta radical: implications for the long-lasting oxidative stress in Alzheimer's disease. J Am Chem Soc 127, 15168-15174. (Pubitemid 41547384)
76. Tabner BJ, El-Agnaf OM, Turnbull S, German MJ, Paleologou KE, HayashiY, Cooper LJ, Fullwood NJ, AllsopD (2005) Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J Biol Chem 280, 35789-35792. (Pubitemid 41633844)
77. Paola D, Domenicotti C, Nitti M, Vitali A, Borghi R, Cottalasso D, Zaccheo D, Odetti P, Strocchi P, Marinari UM, Tabaton M, Pronzato MA (2000) Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun 268, 642-646. (Pubitemid 30119675)
78. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10, 279-288. (Pubitemid 35217581)
79. Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X, Song W (2005) Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm 112, 455-469. (Pubitemid 40868054)
80. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A 101, 2070-2075. (Pubitemid 38229016)
81. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H,Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767. (Pubitemid 32678256)
82. Cetin F, Dincer S (2007) The effect of intrahippocampal beta amyloid (1-42) peptide injection on oxidant and antioxidant status in rat brain. Ann N Y Acad Sci 1100, 510-517. (Pubitemid 47092690)
83. Schaller B (2005) Introduction to serial reviews on free radicals and stroke. Free Radic Biol Med 38, 409-410. (Pubitemid 40247432)
84. Kiris I, Narin C, Gulmen S, Yilmaz N, Sutcu R, Kapucuoglu N, Isparta (2009) Endothelin receptor antagonism by tezosentan attenuates lung injury induced by aortic ischemiareperfusion. Ann Vasc Surg 23, 382-391.
85. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159, 738-745. (Pubitemid 34465046)